Related Experiment Video
Updated: Aug 11, 2026
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Renal phosphate--wasting disorders in childhood
1Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario, and Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada. ward_L@cheo.on.ca
Pediatric Endocrinology Reviews : PER
|February 4, 2006
Summary
This review summarizes recent advances in childhood renal phosphate-wasting disorders, focusing on X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR). It details their diagnosis and treatment, distinguishing them from oncogenic hypophosphatemic osteomalacia (OHO).
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Genetics
Background:
- Renal phosphate-wasting disorders in children present diagnostic and therapeutic challenges.
- Hereditary conditions like X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR) require differentiation from acquired conditions such as oncogenic hypophosphatemic osteomalacia (OHO).
Purpose of the Study:
- To review recent developments in childhood renal phosphate-wasting disorders.
- To emphasize the distinctions between XLH, ADHR, and OHO.
- To provide an overview of clinical manifestations, pathogenesis, diagnosis, and treatment.
Main Methods:
- Literature review of recent scientific publications.
- Synthesis of information on genetic and hormonal signatures.
- Comparative analysis of XLH, ADHR, and OHO.
Main Results:
- Recent genetic and hormonal discoveries are refining the understanding of these disorders.
- Clearer diagnostic criteria are emerging for differentiating hereditary and paraneoplastic conditions.
- Updated treatment strategies are being developed based on new insights.
Conclusions:
- Accurate diagnosis of childhood hypophosphatemic disorders is crucial for effective management.
- Understanding genetic and hormonal pathways is key to advancing treatment for XLH, ADHR, and OHO.
- This review provides valuable information for clinicians managing these complex conditions.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:21Overview of Protein Metabolism
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...